Inbound Relationships |
Type |
Active |
Source |
Characteristic |
Refinability |
Group |
kinagolid 25 mikrogram, oral tablett |
Has presentation strength denominator unit (attribute) |
False |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Apalutamide 60 mg oral tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Diltiazem hydrochloride 120 mg prolonged-release oral tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Diltiazem hydrochloride 120 mg prolonged-release oral tablet |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
cefaklor (som cefaklormonohydrat) 375 milligram, depåtablett |
Has unit of presentation |
False |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
cefaklor (som cefaklormonohydrat) 375 milligram, depåtablett |
Has presentation strength denominator unit (attribute) |
False |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Disopyramide (as disopyramide phosphate) 250 mg prolonged-release oral tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Disopyramide (as disopyramide phosphate) 250 mg prolonged-release oral tablet |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Clarithromycin 500 mg prolonged-release oral tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Clarithromycin 500 mg prolonged-release oral tablet |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
karbidopa (som karbidopamonohydrat) 25 milligram och levodopa 100 milligram, depåtablett |
Has unit of presentation |
False |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
karbidopa (som karbidopamonohydrat) 25 milligram och levodopa 100 milligram, depåtablett |
Has presentation strength denominator unit (attribute) |
False |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
karbidopa (som karbidopamonohydrat) 25 milligram och levodopa 100 milligram, depåtablett |
Has presentation strength denominator unit (attribute) |
False |
Tablet (unit of presentation) |
Inferred relationship |
Some |
2 |
Aspirin 300 mg gastro-resistant oral tablet |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Aspirin 300 mg gastro-resistant oral tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Product containing precisely bupropion hydrochloride 150 milligram/1 each prolonged-release oral tablet (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Product containing precisely bupropion hydrochloride 150 milligram/1 each prolonged-release oral tablet (clinical drug) |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Product containing precisely carbamazepine 400 milligram/1 each prolonged-release oral tablet (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Product containing precisely carbamazepine 400 milligram/1 each prolonged-release oral tablet (clinical drug) |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Product containing precisely diclofenac sodium 25 milligram/1 each gastro-resistant oral tablet (clinical drug) |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Product containing precisely diclofenac sodium 25 milligram/1 each gastro-resistant oral tablet (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Product containing precisely diclofenac sodium 100 milligram/1 each prolonged-release oral tablet (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Product containing precisely diclofenac sodium 100 milligram/1 each prolonged-release oral tablet (clinical drug) |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Bumetanide 500 microgram and potassium chloride 573 mg prolonged-release oral tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
2 |
Bumetanide 500 microgram and potassium chloride 573 mg prolonged-release oral tablet |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Bumetanide 500 microgram and potassium chloride 573 mg prolonged-release oral tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Product containing precisely calcium carbonate 1.5 gram/1 each conventional release chewable tablet (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Product containing precisely calcium carbonate 1.5 gram/1 each conventional release chewable tablet (clinical drug) |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Product containing precisely bisacodyl 5 milligram/1 each gastro-resistant oral tablet (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Product containing precisely bisacodyl 5 milligram/1 each gastro-resistant oral tablet (clinical drug) |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Product containing precisely calcium carbonate 2.5 gram/1 each conventional release chewable tablet (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Product containing precisely calcium carbonate 2.5 gram/1 each conventional release chewable tablet (clinical drug) |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Calcium carbonate 1.25 g chewable tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Calcium carbonate 1.25 g chewable tablet |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Calcium carbonate 1.25 g effervescent oral tablet |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Product containing precisely dihydrocodeine tartrate 90 milligram/1 each prolonged-release oral tablet (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Product containing precisely dihydrocodeine tartrate 90 milligram/1 each prolonged-release oral tablet (clinical drug) |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Diclofenac sodium 50 mg gastro-resistant oral tablet |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Diclofenac sodium 50 mg gastro-resistant oral tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Dinoprostone 3 mg vaginal tablet |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Dinoprostone 3 mg vaginal tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Product containing precisely apomorphine hydrochloride 3 milligram/1 each conventional release sublingual tablet (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Product containing precisely apomorphine hydrochloride 3 milligram/1 each conventional release sublingual tablet (clinical drug) |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Product containing precisely bezafibrate 400 milligram/1 each prolonged-release oral tablet (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Product containing precisely bezafibrate 400 milligram/1 each prolonged-release oral tablet (clinical drug) |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Product containing precisely dexbrompheniramine maleate 6 milligram and pseudoephedrine sulfate 120 milligram/1 each prolonged-release oral tablet (clinical drug) |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Product containing precisely dexbrompheniramine maleate 6 milligram and pseudoephedrine sulfate 120 milligram/1 each prolonged-release oral tablet (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
2 |
Product containing precisely dexbrompheniramine maleate 6 milligram and pseudoephedrine sulfate 120 milligram/1 each prolonged-release oral tablet (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
karbidopa (som karbidopamonohydrat) 50 milligram och levodopa 200 milligram, depåtablett |
Has presentation strength denominator unit (attribute) |
False |
Tablet (unit of presentation) |
Inferred relationship |
Some |
2 |
karbidopa (som karbidopamonohydrat) 50 milligram och levodopa 200 milligram, depåtablett |
Has unit of presentation |
False |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
karbidopa (som karbidopamonohydrat) 50 milligram och levodopa 200 milligram, depåtablett |
Has presentation strength denominator unit (attribute) |
False |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Product containing precisely doxazosin (as doxazosin mesilate) 8 milligram/1 each prolonged-release oral tablet (clinical drug) |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Product containing precisely doxazosin (as doxazosin mesilate) 8 milligram/1 each prolonged-release oral tablet (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Acamprosate calcium 333 mg gastro-resistant oral tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Acamprosate calcium 333 mg gastro-resistant oral tablet |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Product containing precisely dihydrocodeine tartrate 60 milligram/1 each prolonged-release oral tablet (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Product containing precisely dihydrocodeine tartrate 60 milligram/1 each prolonged-release oral tablet (clinical drug) |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Product containing precisely buprenorphine (as buprenorphine hydrochloride) 400 microgram/1 each conventional release sublingual tablet (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Product containing precisely buprenorphine (as buprenorphine hydrochloride) 400 microgram/1 each conventional release sublingual tablet (clinical drug) |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Alfuzosin hydrochloride 10 mg prolonged-release oral tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Alfuzosin hydrochloride 10 mg prolonged-release oral tablet |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
aminofyllin 225 milligram, depåtablett |
Has presentation strength denominator unit (attribute) |
False |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
aminofyllin 225 milligram, depåtablett |
Has unit of presentation |
False |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Disopyramide (as disopyramide phosphate) 150 mg prolonged-release oral tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Disopyramide (as disopyramide phosphate) 150 mg prolonged-release oral tablet |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Cimetidine 400 mg effervescent oral tablet |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Cimetidine 400 mg effervescent oral tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Product containing precisely aspirin 75 milligram/1 each gastro-resistant oral tablet (clinical drug) |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Product containing precisely aspirin 75 milligram/1 each gastro-resistant oral tablet (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Product containing precisely buprenorphine (as buprenorphine hydrochloride) 8 milligram/1 each conventional release sublingual tablet (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Product containing precisely buprenorphine (as buprenorphine hydrochloride) 8 milligram/1 each conventional release sublingual tablet (clinical drug) |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Product containing precisely carbamazepine 100 milligram/1 each conventional release chewable tablet (clinical drug) |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Product containing precisely carbamazepine 100 milligram/1 each conventional release chewable tablet (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Product containing precisely bendroflumethiazide 2.5 milligram and potassium chloride 573 milligram/1 each prolonged-release oral tablet (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Product containing precisely bendroflumethiazide 2.5 milligram and potassium chloride 573 milligram/1 each prolonged-release oral tablet (clinical drug) |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Product containing precisely bendroflumethiazide 2.5 milligram and potassium chloride 573 milligram/1 each prolonged-release oral tablet (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
2 |
Product containing precisely dihydrocodeine tartrate 120 milligram/1 each prolonged-release oral tablet (clinical drug) |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Product containing precisely dihydrocodeine tartrate 120 milligram/1 each prolonged-release oral tablet (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Product containing precisely doxazosin (as doxazosin mesilate) 4 milligram/1 each prolonged-release oral tablet (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Product containing precisely doxazosin (as doxazosin mesilate) 4 milligram/1 each prolonged-release oral tablet (clinical drug) |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Product containing precisely calcium gluconate 1 gram/1 each conventional release effervescent oral tablet (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Product containing precisely calcium gluconate 1 gram/1 each conventional release effervescent oral tablet (clinical drug) |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Diltiazem hydrochloride 60 mg prolonged-release oral tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Diltiazem hydrochloride 60 mg prolonged-release oral tablet |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Diltiazem hydrochloride 90 mg prolonged-release oral tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Diltiazem hydrochloride 90 mg prolonged-release oral tablet |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Product containing precisely bendroflumethiazide 2.5 milligram and potassium chloride 630 milligram/1 each prolonged-release oral tablet (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
2 |
Product containing precisely bendroflumethiazide 2.5 milligram and potassium chloride 630 milligram/1 each prolonged-release oral tablet (clinical drug) |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Product containing precisely bendroflumethiazide 2.5 milligram and potassium chloride 630 milligram/1 each prolonged-release oral tablet (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Carbamazepine 200 mg chewable tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Carbamazepine 200 mg chewable tablet |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Apomorphine hydrochloride 2 mg sublingual tablet |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Apomorphine hydrochloride 2 mg sublingual tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Product containing precisely darifenacin (as darifenacin hydrobromide) 15 milligram/1 each prolonged-release oral tablet (clinical drug) |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Product containing precisely darifenacin (as darifenacin hydrobromide) 15 milligram/1 each prolonged-release oral tablet (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Buprenorphine (as buprenorphine hydrochloride) 200 microgram sublingual tablet |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Buprenorphine (as buprenorphine hydrochloride) 200 microgram sublingual tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Product containing precisely clomipramine hydrochloride 75 milligram/1 each prolonged-release oral tablet (clinical drug) |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Product containing precisely clomipramine hydrochloride 75 milligram/1 each prolonged-release oral tablet (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Buprenorphine (as buprenorphine hydrochloride) 2 mg sublingual tablet |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Buprenorphine (as buprenorphine hydrochloride) 2 mg sublingual tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |